These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 27529807)

  • 1. Thyrotropin Receptor Antibody (TRAb)-IgM Levels Are Markedly Higher Than TRAb-IgG Levels in Graves' Disease Patients and Controls, and TRAb-IgM Production Is Related to Epstein-Barr Virus Reactivation.
    Kumata K; Nagata K; Matsushita M; Kuwamoto S; Kato M; Murakami I; Fukata S; Hayashi K
    Viral Immunol; 2016 Oct; 29(8):459-463. PubMed ID: 27529807
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epstein-Barr virus reactivation in peripheral B lymphocytes induces IgM-type thyrotropin receptor autoantibody production in patients with Graves' disease.
    Nagata K; Hayashi K; Kumata K; Satoh Y; Osaki M; Nakayama Y; Kuwamoto S; Ichihara Y; Okura T; Matsuzawa K; Miake J; Fukata S; Imamura T
    Endocr J; 2023 Jun; 70(6):619-627. PubMed ID: 36908137
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estradiol Affects Epstein-Barr Virus Reactivation-Induced Thyrotropin Receptor Antibody and Immunoglobulin Production in Graves' Disease Patients and Healthy Controls.
    Hara S; Nagata K; Kumata K; Matsushita M; Kuwamoto S; Kato M; Hayashi K
    Viral Immunol; 2018 Sep; 31(7):486-491. PubMed ID: 30133352
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reactivation of persistent Epstein-Barr virus (EBV) causes secretion of thyrotropin receptor antibodies (TRAbs) in EBV-infected B lymphocytes with TRAbs on their surface.
    Nagata K; Nakayama Y; Higaki K; Ochi M; Kanai K; Matsushita M; Kuwamoto S; Kato M; Murakami I; Iwasaki T; Nanba E; Kimura H; Hayashi K
    Autoimmunity; 2015; 48(5):328-35. PubMed ID: 25759125
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Subclinical Epstein-Barr Virus Primary Infection and Lytic Reactivation Induce Thyrotropin Receptor Autoantibodies.
    Tamoto N; Nagata K; Hara S; Nakayama Y; Kuwamoto S; Matsushita M; Kato M; Hayashi K
    Viral Immunol; 2019 Nov; 32(9):362-369. PubMed ID: 31580214
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epstein-Barr Virus Lytic Reactivation Activates B Cells Polyclonally and Induces Activation-Induced Cytidine Deaminase Expression: A Mechanism Underlying Autoimmunity and Its Contribution to Graves' Disease.
    Nagata K; Kumata K; Nakayama Y; Satoh Y; Sugihara H; Hara S; Matsushita M; Kuwamoto S; Kato M; Murakami I; Hayashi K
    Viral Immunol; 2017 Apr; 30(3):240-249. PubMed ID: 28333576
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The influence of Epstein-Barr virus reactivation in patients with Graves' disease.
    Nagata K; Fukata S; Kanai K; Satoh Y; Segawa T; Kuwamoto S; Sugihara H; Kato M; Murakami I; Hayashi K; Sairenji T
    Viral Immunol; 2011 Apr; 24(2):143-9. PubMed ID: 21449724
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epstein-Barr Virus Lytic Reactivation Induces IgG4 Production by Host B Lymphocytes in Graves' Disease Patients and Controls: A Subset of Graves' Disease Is an IgG4-Related Disease-Like Condition.
    Nagata K; Hara S; Nakayama Y; Higaki K; Sugihara H; Kuwamoto S; Matsushita M; Kato M; Tanio S; Ishiguro K; Hayashi K
    Viral Immunol; 2018 Oct; 31(8):540-547. PubMed ID: 30222515
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Presence of Epstein-Barr virus-infected B lymphocytes with thyrotropin receptor antibodies on their surface in Graves' disease patients and in healthy individuals.
    Nagata K; Higaki K; Nakayama Y; Miyauchi H; Kiritani Y; Kanai K; Matsushita M; Iwasaki T; Sugihara H; Kuwamoto S; Kato M; Murakami I; Nanba E; Kimura H; Hayashi K
    Autoimmunity; 2014 May; 47(3):193-200. PubMed ID: 24467196
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epstein-Barr Virus Reactivation-Induced Immunoglobulin Production: Significance on Autoimmunity.
    Nagata K; Hayashi K
    Microorganisms; 2020 Nov; 8(12):. PubMed ID: 33260824
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High Level Estradiol Induces EBV Reactivation and EBV gp350/220(+)CD138(+) Double-positive B Cell Population in Graves' Disease Patients and Healthy Controls.
    Hara S; Nagata K; Nakayama Y; Higaki K; Matsushita M; Kuwamoto S; Kato M; Hayashi K
    Yonago Acta Med; 2019 Jun; 62(2):240-243. PubMed ID: 31341401
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sensitive thyrotropin and thyrotropin-receptor antibody determinations one month after discontinuation of antithyroid drug treatment as predictors of relapse in Graves' disease.
    Quadbeck B; Hoermann R; Roggenbuck U; Hahn S; Mann K; Janssen OE;
    Thyroid; 2005 Sep; 15(9):1047-54. PubMed ID: 16187913
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunoglobulins of untreated Graves' patients with or without thyrotropin receptor antibody (determined by porcine thyrocytes) universally elicit potent thyroid hormone-releasing activity in cultured human thyroid follicles.
    Sato K; Yamazaki K; Yamada E; Kanaji Y; Miura M; Obara T
    Thyroid; 1999 Oct; 9(10):979-88. PubMed ID: 10560951
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of TSH receptor antibody by 'natural in vivo human assay' in neonates born to mothers with Graves' disease.
    Tamaki H; Amino N; Iwatani Y; Tachi J; Kimura M; Mitsuda N; Ichihara K; Tanizawa O; Miyai K
    Clin Endocrinol (Oxf); 1989 May; 30(5):493-503. PubMed ID: 2575017
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Production of thyrotropin receptor antibodies in acute phase of infectious mononucleosis due to Epstein-Barr virus primary infection: a case report of a child.
    Nagata K; Okuno K; Ochi M; Kumata K; Sano H; Yoneda N; Ueyama J; Matsushita M; Kuwamoto S; Kato M; Murakami I; Kanzaki S; Hayashi K
    Springerplus; 2015; 4():456. PubMed ID: 26322262
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Isolation of Epstein-Barr-virus-transformed lymphocytes producing IgG class monoclonal antibodies using a magnetic cell separator (MACS): preparation of thyroid-stimulating IgG antibodies from patients with Graves' disease.
    Li H; Akamizu T; Okuda J; Sugawa H; Matsuda F; Tsubata T; Mori T
    Biochem Biophys Res Commun; 1995 Feb; 207(3):985-93. PubMed ID: 7864905
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sensitive thyroid-stimulating antibody assay with high concentrations of polyethylene glycol for the diagnosis of Graves' disease.
    Takasu N; Kamijo K; Sato Y; Yoshimura H; Nagata A; Ochi Y
    Clin Exp Pharmacol Physiol; 2004; 31(5-6):314-9. PubMed ID: 15191404
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TSH-receptor antibody measurement for differentiation of hyperthyroidism into Graves' disease and multinodular toxic goitre: a comparison of two competitive binding assays.
    Pedersen IB; Knudsen N; Perrild H; Ovesen L; Laurberg P
    Clin Endocrinol (Oxf); 2001 Sep; 55(3):381-90. PubMed ID: 11589682
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum thyroglobulin concentration as an indicator for assessing thyroid stimulation in patients with Graves' disease during antithyroid drug therapy.
    Aizawa T; Ishihara M; Koizumi Y; Hashizume K; Takasu N; Yamada T; Kobayashi I; Watanabe T; Shimizu Z
    Am J Med; 1990 Aug; 89(2):175-80. PubMed ID: 2166430
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TSBAb (TSH-stimulation blocking antibody) and TSAb (thyroid stimulating antibody) in TSBAb-positive patients with hypothyroidism and Graves' patients with hyperthyroidism.
    Takasu N; Yamashiro K; Ochi Y; Sato Y; Nagata A; Komiya I; Yoshimura H
    Horm Metab Res; 2001 Apr; 33(4):232-7. PubMed ID: 11383928
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.